|
Brussels, Belgium, March 3, 2008 - Euroscreen S.A. has completed a license agreement with AstraZeneca UK Ltd, for access to its worldwide portfolio of CCR5 patent rights. Financial details of the agreement were not disclosed.
Euroscreen is the exclusive licensor of rights originally generated by ICOS, Human Genome Sciences, and Euroscreen for this combined portfolio of CCR5 patents for non-antibody therapeutic development.
Commenting on the announcement, Dr. Jean Combalbert, CEO of Euroscreen, said, ”In adding a big player like AstraZeneca to our sub-licensees, we are now obtaining recognition that the application of our CCR5 patent rights is not limited to HIV but is also useful in important new indications to unmet therapeutic needs such as rheumatoid arthritis. CCR5 is becoming an important target for not just the ongoing anti-HIV drug applications. AstraZeneca is in phase II with its antagonist for a non-HIV application and another sub-licensee – Pfizer - is in announced phase II studies for the same indication with Selzentry™ already registered for anti-HIV application”.
-ends-
For further licensing Information, please contact:
Euroscreen S.A.
Tel: +32 71 348 500
email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Vincent Lannoy, Ph.D.
Business Development and Licensing Manager
Jean Combalbert, Ph.D.
Chief Executive Officer
About Euroscreen S.A.
EUROSCREEN is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs. Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, EUROSCREEN is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets. EUROSCREEN pursues a dual business model strategy of combining its internal programs on high value targets (Euroscreen DRUG DISCOVERY) with its fully dedicated Business Unit (Euroscreen FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world. EUROSCREEN has developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2. EUROSCREEN has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Novartis and Pfizer.
|
News & Press Releases